ELAN vs. ONC, BNTX, TEVA, INSM, SMMT, ITCI, GMAB, RDY, QGEN, and MRNA
Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Elanco Animal Health vs. Its Competitors
BeOne Medicines (NASDAQ:ONC) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.
Elanco Animal Health has a net margin of 8.43% compared to BeOne Medicines' net margin of -9.40%. Elanco Animal Health's return on equity of 7.54% beat BeOne Medicines' return on equity.
Elanco Animal Health has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
BeOne Medicines has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500.
48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by insiders. Comparatively, 0.9% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
BeOne Medicines currently has a consensus price target of $320.67, suggesting a potential upside of 26.26%. Elanco Animal Health has a consensus price target of $15.33, suggesting a potential upside of 3.29%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Elanco Animal Health.
In the previous week, Elanco Animal Health had 5 more articles in the media than BeOne Medicines. MarketBeat recorded 8 mentions for Elanco Animal Health and 3 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.51 beat Elanco Animal Health's score of 0.43 indicating that BeOne Medicines is being referred to more favorably in the media.
Summary
Elanco Animal Health beats BeOne Medicines on 10 of the 16 factors compared between the two stocks.
Get Elanco Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Elanco Animal Health Competitors List
Related Companies and Tools
This page (NYSE:ELAN) was last updated on 7/9/2025 by MarketBeat.com Staff